NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced that management will present at the Piper Sandler 37th Annual Healthcare Conference in New York City. Participating will be Ben Zeskind, Co-founder and Chief Executive Officer, Igor Matushansky M.D., Chief Medical Officer, Harold “E.B.” Brakewood, Chief Business Officer and Mallory Morales, CPA, Chief Accountin ...

Core Viewpoint - Immuneering Corporation has successfully closed a private placement, raising approximately $25 million from institutional and accredited investors, aimed at advancing its oncology drug development efforts [1][2]. Group 1: Private Placement Details - The private placement involved the sale of 6,329,113 unregistered shares of Class A common stock at a price of $3.95 per share, along with purchase warrants for an additional 2,848,096 shares at an exercise price of $5.50 per share [2]. - The pre-funded warrants were issued at a price of $3.949 per share, reflecting the common stock price minus a nominal exercise price [2]. - Investors received registration rights as part of the transaction, and the purchase warrants are exercisable for five years post-registration [2]. Group 2: Company Overview - Immuneering is a clinical-stage oncology company focused on developing Deep Cyclic Inhibitors, with its lead product candidate, atebimetinib (IMM-1-104), currently in a Phase 2a trial for advanced solid tumors, including pancreatic cancer [5]. - The company aims to improve the durability and tolerability of cancer treatments and expand indications for MAPK pathway-driven tumors [5].